Escitalopram alters gene expression and HPA axis reactivity in rats following chronic overexpression of corticotropin-releasing factor from the central amygdala

[1]  Nedjeljko Frančula.  The National Academies Press , 2013 .

[2]  David L. Walker,et al.  EFFECTS OF CONTINUOUSLY ENHANCED CORTICOTROPIN RELEASING FACTOR EXPRESSION WITHIN THE BED NUCLEUS OF THE STRIA TERMINALIS ON CONDITIONED AND UNCONDITIONED ANXIETY , 2012, Molecular Psychiatry.

[3]  K. Ressler,et al.  Chronic overexpression of corticotropin-releasing factor from the central amygdala produces HPA axis hyperactivity and behavioral anxiety associated with gene-expression changes in the hippocampus and paraventricular nucleus of the hypothalamus , 2012, Psychoneuroendocrinology.

[4]  R. Godbout,et al.  Escitalopram reduces circulating pro-inflammatory cytokines and improves depressive behavior without affecting sleep in a rat model of post-cardiac infarct depression , 2011, Behavioural Brain Research.

[5]  M. Fava,et al.  Changes in Depressive Symptoms and Social Functioning in the Sequenced Treatment Alternatives to Relieve Depression Study , 2011, The Journal of nervous and mental disease.

[6]  F. Zitman,et al.  Antidepressant use and salivary cortisol in depressive and anxiety disorders , 2011, European Neuropsychopharmacology.

[7]  B. Guthrie,et al.  Trends in primary care antidepressant prescribing 1995-2007: a longitudinal population database analysis. , 2011, The British journal of general practice : the journal of the Royal College of General Practitioners.

[8]  A. Chen,et al.  Prolonged and site-specific over-expression of corticotropin-releasing factor reveals differential roles for extended amygdala nuclei in emotional regulation , 2011, Molecular Psychiatry.

[9]  C. Otte,et al.  Changes in cortisol secretion during antidepressive treatment and cognitive improvement in patients with major depression: A longitudinal study , 2011, Psychoneuroendocrinology.

[10]  A. Goate,et al.  Elevated cortisol in older adults with generalized anxiety disorder is reduced by treatment: a placebo-controlled evaluation of escitalopram. , 2011, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[11]  T. Raju,et al.  Chronic escitalopram treatment restores spatial learning, monoamine levels, and hippocampal long-term potentiation in an animal model of depression , 2011, Psychopharmacology.

[12]  C. Nemeroff,et al.  The role of corticotropin-releasing hormone in the pathophysiology of depression: therapeutic implications. , 2011, Current topics in medicinal chemistry.

[13]  I. Heuser,et al.  A single DEX/CRH test in male drug-free depressed patients is associated with the clinical response to treatment with fluoxetine. , 2010, Journal of psychiatric research.

[14]  T. B. Üstün,et al.  Days out of role due to common physical and mental conditions: results from the WHO World Mental Health surveys , 2010, Molecular Psychiatry.

[15]  G. Lynch,et al.  Hippocampal Dysfunction and Cognitive Impairments Provoked by Chronic Early-Life Stress Involve Excessive Activation of CRH Receptors , 2010, The Journal of Neuroscience.

[16]  David R. Williams,et al.  Associations of serious mental illness with earnings: results from the WHO World Mental Health surveys , 2010, British Journal of Psychiatry.

[17]  G. Lynch,et al.  Correlated memory defects and hippocampal dendritic spine loss after acute stress involve corticotropin-releasing hormone signaling , 2010, Proceedings of the National Academy of Sciences.

[18]  S. Batchelder,et al.  Escitalopram versus placebo in the treatment of dysthymic disorder , 2010, International clinical psychopharmacology.

[19]  R. Kessler,et al.  Employer burden of mild, moderate, and severe major depressive disorder: mental health services utilization and costs, and work performance , 2010, Depression and anxiety.

[20]  D. Bylund,et al.  Treatment with escitalopram but not desipramine decreases escape latency times in a learned helplessness model using juvenile rats , 2009, Psychopharmacology.

[21]  Florian Holsboer,et al.  Central CRH system in depression and anxiety--evidence from clinical studies with CRH1 receptor antagonists. , 2008, European journal of pharmacology.

[22]  K. Kõiv,et al.  Rat behavior after chronic variable stress and partial lesioning of 5-HT-ergic neurotransmission: Effects of citalopram , 2008, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[23]  M. Owens,et al.  Preparation of antidepressants for use in preclinical research. , 2007, The international journal of neuropsychopharmacology.

[24]  B. Harvey,et al.  Early life trauma decreases glucocorticoid receptors in rat dentate gyrus upon adult re-stress: Reversal by escitalopram , 2006, Neuroscience.

[25]  M. Stein,et al.  Role of corticotropin releasing factor in anxiety disorders: A translational research perspective , 2006, Hormones and Behavior.

[26]  Michael Davis,et al.  Amygdala BDNF signaling is required for consolidation but not encoding of extinction , 2006, Nature Neuroscience.

[27]  D. Bartsch,et al.  Selective effects of citalopram in a mouse model of stress-induced anhedonia with a control for chronic stress , 2006, Behavioural pharmacology.

[28]  C. Nemeroff,et al.  Ketamine-xylazine-acepromazine anesthesia and postoperative recovery in rats. , 2006, Journal of the American Association for Laboratory Animal Science : JAALAS.

[29]  Ove Wiborg,et al.  Hippocampal Cytogenesis Correlates to Escitalopram-Mediated Recovery in a Chronic Mild Stress Rat Model of Depression , 2006, Neuropsychopharmacology.

[30]  R. Paylor,et al.  The use of behavioral test batteries, II: Effect of test interval , 2006, Physiology & Behavior.

[31]  C. Eap,et al.  Neuropeptide Y and corticotropin-releasing hormone in CSF mark response to antidepressive treatment with citalopram. , 2005, The international journal of neuropsychopharmacology.

[32]  C. Eap,et al.  Long-term citalopram administration reduces responsiveness of HPA axis in patients with major depression: relationship with S-citalopram concentrations in plasma and cerebrospinal fluid (CSF) and clinical response , 2005, Psychopharmacology.

[33]  Olga V. Demler,et al.  Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. , 2005, Archives of general psychiatry.

[34]  D. Jessop,et al.  Differential actions of acute and chronic citalopram on the rodent hypothalamic-pituitary-adrenal axis response to acute restraint stress. , 2005, The Journal of endocrinology.

[35]  Olga V. Demler,et al.  Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. , 2005, Archives of general psychiatry.

[36]  M. Frotscher,et al.  Hippocampal corticotropin releasing hormone: pre- and postsynaptic location and release by stress , 2004, Neuroscience.

[37]  J. Seckl,et al.  Differential regulation of variant glucocorticoid receptor mRNAs in the rat hippocampus by the antidepressant fluoxetine. , 2004, Brain research. Molecular brain research.

[38]  Joseph E. LeDoux,et al.  The selective serotonin reuptake inhibitor citalopram increases fear after acute treatment but reduces fear with chronic treatment: a comparison with tianeptine , 2004, Biological Psychiatry.

[39]  D. Overstreet,et al.  Antidepressant effects of citalopram and CRF receptor antagonist CP-154,526 in a rat model of depression. , 2004, European journal of pharmacology.

[40]  Michael Davis,et al.  Brain-Derived Neurotrophic Factor and Tyrosine Kinase Receptor B Involvement in Amygdala-Dependent Fear Conditioning , 2004, The Journal of Neuroscience.

[41]  S. Claes.  Corticotropin‐releasing hormone (CRH) in psychiatry: from stress to psychopathology , 2004, Annals of medicine.

[42]  P. Kelly,et al.  Differential regulation of corticosteroid receptors by monoamine neurotransmitters and antidepressant drugs in primary hippocampal culture , 2003, Neuroscience.

[43]  C. Nemeroff,et al.  The Effects of Chronic Treatment with the Mood Stabilizers Valproic Acid and Lithium on Corticotropin-Releasing Factor Neuronal Systems , 2003, Journal of Pharmacology and Experimental Therapeutics.

[44]  F. Holsboer,et al.  Corticotropin-releasing factor receptors 1 and 2 in anxiety and depression. , 2002, Current opinion in pharmacology.

[45]  F. Gage,et al.  Delivery of the Cre recombinase by a self-deleting lentiviral vector: Efficient gene targeting in vivo , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[46]  Richard Paylor,et al.  The use of behavioral test batteries: Effects of training history , 2001, Physiology & Behavior.

[47]  J. Seckl,et al.  Short-term administration of fluoxetine and venlafaxine decreases corticosteroid receptor mRNA expression in the rat hippocampus , 2001, Neuroscience Letters.

[48]  C. Nemeroff,et al.  Effects of Sodium Valproate on Corticotropin-Releasing Factor Systems in Rat Brain , 2001, Neuropsychopharmacology.

[49]  D. Baker,et al.  Corticotropin-releasing hormone in depression and post-traumatic stress disorder , 2001, Peptides.

[50]  M. Millan,et al.  Citalopram reduces social interaction in rats by activation of serotonin (5-HT)2C receptors , 2000, Neuropharmacology.

[51]  C. Nemeroff,et al.  Chronic Administration of the Triazolobenzodiazepine Alprazolam Produces Opposite Effects on Corticotropin-Releasing Factor and Urocortin Neuronal Systems , 2000, The Journal of Neuroscience.

[52]  T. Kinoshita,et al.  Long‐Term Treatment with Antidepressants Increases Glucocorticoid Receptor Binding and Gene Expression in Cultured Rat Hippocampal Neurones , 1999, Journal of neuroendocrinology.

[53]  F. Chaouloff,et al.  Effects of repeated fluoxetine on anxiety-related behaviours, central serotonergic systems, and the corticotropic axis in SHR and WKY rats , 1999, Neuropharmacology.

[54]  Jensen,et al.  Acute and Long‐Term Treatments with the Selective Serotonin Reuptake Inhibitor Citalopram Modulate the HPA Axis Activity at Different Levels in Male Rats , 1999, Journal of neuroendocrinology.

[55]  D. Trono,et al.  Self-Inactivating Lentivirus Vector for Safe and Efficient In Vivo Gene Delivery , 1998, Journal of Virology.

[56]  Fred H. Gage,et al.  Development of a Self-Inactivating Lentivirus Vector , 1998, Journal of Virology.

[57]  F. Gage,et al.  In Vivo Gene Delivery and Stable Transduction of Nondividing Cells by a Lentiviral Vector , 1996, Science.

[58]  Division on Earth.  Guide for the Care and Use of Laboratory Animals , 1996 .

[59]  M. Wong,et al.  Corticotropin Releasing Hormone in the Pathophysiology of Melancholic and Atypical Depression and in the Mechanism of Action of Antidepressant Drugs , 1995, Annals of the New York Academy of Sciences.

[60]  I. Heuser,et al.  The combined dexamethasone/CRH test: a refined laboratory test for psychiatric disorders. , 1994, Journal of psychiatric research.

[61]  M. D. De Bellis,et al.  Association of fluoxetine treatment with reductions in CSF concentrations of corticotropin-releasing hormone and arginine vasopressin in patients with major depression. , 1993, The American journal of psychiatry.

[62]  C. Nemeroff,et al.  Physiology and pharmacology of corticotropin-releasing factor. , 1991, Pharmacological reviews.

[63]  C. Nemeroff,et al.  Plasma dexamethasone concentrations and the dexamethasone suppression test , 1990, Biological Psychiatry.

[64]  E. D. De Souza,et al.  Effects of chronic antidepressant and benzodiazepine treatment on corticotropin-releasing-factor receptors in rat brain and pituitary. , 1989, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.

[65]  F. Holsboer,et al.  Human corticotropin releasing hormone: Clinical studies in patients with affective disorders, alcoholism, panic disorder and in normal controls , 1988, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[66]  W. Vale,et al.  Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin. , 1982, Science.

[67]  U. Lewitzka,et al.  Impact of citalopram on the HPA system. A study of the combined DEX/CRH test in 30 unipolar depressed patients. , 2012, Journal of psychiatric research.

[68]  R. Hargreaves,et al.  Drug Discovery for Psychiatric Disorders , 2012 .

[69]  K. Ressler,et al.  Continuous expression of corticotropin-releasing factor in the central nucleus of the amygdala emulates the dysregulation of the stress and reproductive axes , 2009, Molecular Psychiatry.

[70]  David A Morilak,et al.  Chronic Unpredictable Stress Induces a Cognitive Deficit and Anxiety-Like Behavior in Rats that is Prevented by Chronic Antidepressant Drug Treatment , 2008, Neuropsychopharmacology.

[71]  T. Baram,et al.  Corticotropin‐releasing hormone (CRH)‐containing neurons in the immature rat hippocampal formation: Light and electron microscopic features and colocalization with glutamate decarboxylase and parvalbumin , 1998, Hippocampus.

[72]  R. Valentino,et al.  Antidepressant interactions with corticotropin-releasing factor in the noradrenergic nucleus locus coeruleus. , 1991, Psychopharmacology bulletin.

[73]  G. Paxinos,et al.  The Rat Brain in Stereotaxic Coordinates , 1983 .